PB2129 PRETREATMENT D‐DIMER LEVELS PROVIDE PROGNOSTIC INFORMATION IN PATIENTS WITH MULTIPLE MYELOMA

Background:High D‐dimer levels are associated with poor overall survival in patients with general cancer.Aims:This retrospective study aimed to investigate the prognostic value of D‐dimer levels in patients with multiple myeloma (MM).MethodsA total of 214 patients newly diagnosed with MM were retrospectively enrolled. The correlation between pre‐treatment plasma D‐dimer levels and clinical factors was evaluated. The cut‐off value of D‐dimer for predicting survival was set as 0.8 μg/ml based on receiver operating curve analysis. Patients with a D‐dimer level ≥ 0.8 mg/ml had more adverse clinical features, including advanced R‐ISS stage, higher International Myeloma Working Group risk stratification, more abnormal chromosome, and increased serum creatinine level. The prognostic value of d‐dimer levels was explored.Results:Patients with a D‐dimer level ≥ 0.8 mg/ml showed poor overall survival (OS) and progression‐free survival (PFS). Multivariate analyses revealed that the D‐dimer levels were independent predictors of OS and PFS (hazard ratio = 10.15 and 0.27, 95% confidence interval = 4.86–21.19 and 0.18–0.42, P < 0.001 and P < 0.001).Summary/Conclusion:In conclusion, D‐dimer levels might be considered as a simple and effective prognostic marker in patients with MM.